Antihypertyensive Drugs used during Pregnancy: an Evaluation
BACKGROUND & OBJECTIVES: Hypertensive disorders during pregnancy are a leading cause of maternal mortality occurring in 5-10 percent of pregnancies. While the goal of treatment is to reduce maternal risk, the agents selected must be efficacious and safe for the foetus. Thus, the present study was carried out with objectives to assess the prevalence of hypertensive disorders during pregnancy, the prescribing pattern to treat these conditions and to monitor adverse drug reactions. METHODOLGY: A six months prospective study was carried out at a tertiary care hospital, after obtaining Ethical clearance. Data was collected from the antenatal cards and case sheets of all pregnant women diagnosed with elevated BP and admitted to the wards. Classification of hypertensive disorders of the patients were performed according to the criteria by Davey and Mac Gillivray, American College of Obstetrics & Gynecology (ACOG) and endorsed by the International Society for the Study of Hypertension in Pregnancy (ISSHP). RESULTS & CONCLUSION: 152 patients met inclusion criteria. Prevalence of hypertensive disorders during pregnancy was found to be 12.2%. Based on the classification , 65% of patients had Gestational Hypertension, 26% had Pre-eclampsia/Eclampsia and 9% had Chronic Hypertension. The most commonly prescribed medicines to treat the hypertensive disorders during pregnancy were Nifedipine, Methyldopa, MgSO4, Atenolol, Furosemide and their combinations. Nifedipine was widely used in patients with Gestational Hypertension (14.1%) and Pre-eclampsia/Eclampsia (22.5%). For Chronic Hypertension, a combination of Nifedipine and Methyldopa (38.5%) were prescribed. The treatment given for the management of hypertensive disorders during pregnancy was found to be at par with the guidelines.